DAWN
Day One Biopharmaceuticals Inc

1,786
Mkt Cap
$721.12M
Volume
2.2M
52W High
$16.76
52W Low
$5.64
PE Ratio
-7.72
DAWN Fundamentals
Price
$7.04
Prev Close
$7.04
Open
$7.02
50D MA
$7.26
Beta
1.12
Avg. Volume
1.08M
EPS (Annual)
-$1.02
P/B
1.56
Rev/Employee
$724,646.41
Loading...
Loading...
News
all
press releases
Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 234.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·14h ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 241.59%: Read This Before Placing a Bet
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 241.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·17d ago
News Placeholder
Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last?
Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·25d ago
News Placeholder
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·1mo ago
News Placeholder
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 303.5% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·3mo ago
News Placeholder
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
chainwire·6mo ago
News Placeholder
Futures Drop As Japan, European Stocks Tumble On AI Bubble Bursting Fears
Futures Drop As Japan, European Stocks Tumble On AI Bubble Bursting Fears US equity futures are lower but well off their worst levels, after a rout in Japan sent the Nikkei tumbling...
Zero Hedge·1y ago
News Placeholder
Piper Sandler Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Day One Biopharmaceuticals (DAWN Research Report) today and set a price target...
TipRanks Financial Blog·1y ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by Piper Sandler
Day One Biopharmaceuticals (NASDAQ:DAWN Get Free Report)s stock had its overweight rating reiterated by equities research analysts at Piper Sandler in a research report...
Zolmax·2y ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns "Overweight" Rating from Piper Sandler
Day One Biopharmaceuticals (NASDAQ:DAWN Get Free Report)s stock had its overweight rating reaffirmed by equities research analysts at Piper Sandler in a research note...
Ticker Report·2y ago

Latest DAWN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.